Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) is a Healthcare company (Biotechnology) with a market capitalization of $1.9B. The Maz Rating grades it against the other companies in its sector.
Harmony Biosciences Holdings, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $32.80, Harmony Biosciences Holdings, Inc. trades at 10.6x trailing earnings, 1.9x sales and 1.8x book value, with an EV/EBITDA of 5.3. Over the last twelve months it generated about $991M of revenue and $181M of net income. It runs a gross margin of 74.0%, an operating margin of 22.2% and a net margin of 18.1%. It shows return on equity of 18.5%, return on invested capital of 13.7% and a free cash flow yield of 16.7%. On the balance sheet: a debt-to-equity ratio of 0.14 and a current ratio of 3.44. Over the past 52 weeks the share price ranged from $25.90 to $43.49, with a beta of 0.98.
Harmony Biosciences Holdings, Inc. does not currently pay a dividend.
13 Wall Street analyst ratings cover the stock: 8 Buy, 3 Hold and 2 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Harmony Biosciences Holdings, Inc. (HRMY) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 6.65% / 30% · (Cash+Inv) / Mkt Cap (36m) 46.9% / 30% · Interest income / Revenue 3.13% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 6.65% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 34.4% / 33% · Receivables / Mkt Cap (36m) 5.70% / 49% · Interest income / Revenue 3.13% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 6.65% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 34.4% / 33.33% · Receivables / Mkt Cap (24m) 5.70% / 33.33% · Interest income / Revenue 3.13% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 13.7% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 52.9% / 33.33% · Receivables / Avg Assets (4Q) 8.23% / 33.33% · Interest income / Revenue 3.13% / 5% | Fail |
| FTSE | Debt / Total Assets 10.1% / 33.33% · (Cash+ST Inv) / Total Assets 52.2% / 33.33% · (Cash+Recv) / Total Assets 60.8% / 33.33% · Interest income / Revenue 3.13% / 5% | Fail |
No. As of September 2026, Harmony Biosciences Holdings, Inc. (HRMY) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Harmony Biosciences Holdings, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m).
About 3.13% of each dividend: Harmony Biosciences Holdings, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.